Investigation of Risk Factors Linked to Bloodstream Infections from Candida parapsilosis in Children and Factors Influencing Fluconazole Resistance: A 15-Year Retrospective Cohort Study - Scorecard - MDSpire
Advertisement
Investigation of Risk Factors Linked to Bloodstream Infections from Candida parapsilosis in Children and Factors Influencing Fluconazole Resistance: A 15-Year Retrospective Cohort Study
Clinical Scorecard: Investigation of Risk Factors Linked to Bloodstream Infections from Candida parapsilosis in Children and Factors Influencing Fluconazole Resistance: A 15-Year Retrospective Cohort Study
At a Glance
Category
Detail
Condition
Candidemia caused by Candida parapsilosis
Key Mechanisms
Emergence of fluconazole-resistant strains and associated risk factors
Target Population
Pediatric patients aged over one month
Care Setting
Tertiary care facility, specifically a children's hospital
Key Highlights
C. parapsilosis is the second most prevalent cause of candidemia in children.
Fluconazole resistance rates exceed 40-60% in some regions.
No association between fluconazole resistance and higher mortality rates.
Identifying clinical risk factors is crucial for guiding empirical therapy.
Limited pediatric studies on C. parapsilosis highlight the need for further research.
Guideline-Based Recommendations
Diagnosis
Candidemia is diagnosed through blood culture isolation of fungi in symptomatic patients.
Management
Empirical antifungal therapy should consider local resistance patterns.
Monitoring & Follow-up
Monitor for clinical symptoms and laboratory findings post-antifungal treatment.
Risks
Prior antimicrobial treatment and invasive procedures increase candidemia risk.
Patient & Prescribing Data
Pediatric patients with candidemia, excluding neonates and preterm infants.
Fluconazole exposure defined as 6-12 mg/kg per day within one month of candidemia.
Clinical Best Practices
Implement stringent infection control measures to manage outbreaks.
Conduct regular antifungal susceptibility testing to guide treatment decisions.
Collect comprehensive clinical data for ongoing epidemiological studies.
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.
